Amarin Gears Up to Report Q2 Earnings: Here's What to Expect

Key Takeaways AMRN is set to report Q2 results on July 30, with investor focus on Vascepa/Vazkepa sales.U.S. Vascepa sales are likely to have declined, while EU Vazkepa revenues are likely to have risen.Expense reduction from cost-cutting measures may have lowered operating spend in the to-be-reported quarter.We expect investors to focus on the sales performance of Amarin Corporation’s (AMRN) sole marketed drug, Vascepa/Vazkepa, when it reports second-quarter 2025 results on July 30, before market open. The ...